These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Benzodiazepines and delirium: the best option for the right patient. Gusmao-Flores D; Carvalho JP; Quarantini LC Crit Care Med; 2013 Oct; 41(10):e295-6. PubMed ID: 24060798 [No Abstract] [Full Text] [Related]
3. Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. Skrobik Y; Leger C; Cossette M; Michaud V; Turgeon J Crit Care Med; 2013 Apr; 41(4):999-1008. PubMed ID: 23385102 [TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Martino A; Campa D; Buda G; Sainz J; García-Sanz R; Jamroziak K; Reis RM; Weinhold N; Jurado M; Ríos R; Szemraj-Rogucka Z; Marques H; Szemraj J; Stein A; Kumar R; Orciuolo E; Gemignani F; Landi S; Goldschmidt H; Petrini M; Dumontet C; Canzian F; Rossi AM Leukemia; 2012 Jun; 26(6):1419-22. PubMed ID: 22182917 [No Abstract] [Full Text] [Related]
5. [Polymorphism of ABCB1 and ABCG2 genes encoding drug transporters and their investigation by pyrosequencing]. Dribnokhodova OP; Mironov KO; Dunaeva EA; Shipulin GA Eksp Klin Farmakol; 2012; 75(10):29-36. PubMed ID: 23240156 [TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153 [TBL] [Abstract][Full Text] [Related]
7. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Yanagisawa R; Katsuyama Y; Shigemura T; Saito S; Tanaka M; Nakazawa Y; Sakashita K; Shiohara M; Koike K Bone Marrow Transplant; 2011 Jan; 46(1):90-7. PubMed ID: 20383212 [TBL] [Abstract][Full Text] [Related]
8. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292 [TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410 [TBL] [Abstract][Full Text] [Related]
10. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513. Salphati L; Plise EG; Li G Eur J Pharm Sci; 2009 Jun; 37(3-4):463-8. PubMed ID: 19491037 [TBL] [Abstract][Full Text] [Related]
11. Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Cascorbi I; Flüh C; Remmler C; Haenisch S; Faltraco F; Grumbt M; Peters M; Brenn A; Thal DR; Warzok RW; Vogelgesang S Pharmacogenomics; 2013 Apr; 14(5):485-94. PubMed ID: 23556446 [TBL] [Abstract][Full Text] [Related]
12. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Dörr J; Bitsch A; Schmailzl KJ; Chan A; von Ahsen N; Hummel M; Varon R; Lill CM; Vogel HP; Zipp F; Paul F Neurology; 2009 Sep; 73(12):991-3. PubMed ID: 19770476 [No Abstract] [Full Text] [Related]
13. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400 [TBL] [Abstract][Full Text] [Related]
14. Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacodynamics of fentanyl. Ziesenitz VC; van den Anker JN Int J Clin Pharmacol Ther; 2013 Dec; 51(12):991-2. PubMed ID: 24161162 [No Abstract] [Full Text] [Related]
15. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Chen M; Xue X; Wang F; An Y; Tang D; Xu Y; Wang H; Yuan Z; Gao W; Wei J; Zhang J; Miao Y Oncol Rep; 2012 Jan; 27(1):265-9. PubMed ID: 21956451 [TBL] [Abstract][Full Text] [Related]
16. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines. Tomiyasu H; Watanabe M; Sugita K; Goto-Koshino Y; Fujino Y; Ohno K; Sugano S; Tsujimoto H Anticancer Res; 2013 Dec; 33(12):5317-23. PubMed ID: 24324065 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Cascorbi I; Haenisch S Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922 [TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500 [TBL] [Abstract][Full Text] [Related]
19. [Drug distribution, resistance to cytostatics and disease pathogenesis: many roles of ABC proteins]. Lehmann S; Rane A Lakartidningen; 2004 Jan; 101(4):282-7. PubMed ID: 14979001 [No Abstract] [Full Text] [Related]
20. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Campa D; Müller P; Edler L; Knoefel L; Barale R; Heussel CP; Thomas M; Canzian F; Risch A Int J Cancer; 2012 Dec; 131(12):2920-8. PubMed ID: 22473764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]